<DOC>
	<DOCNO>NCT01428284</DOCNO>
	<brief_summary>The purpose study assess effect multiple dos probenecid multiple-dose pharmacokinetics canagliflozin metabolites healthy volunteer . Safety tolerability also assess .</brief_summary>
	<brief_title>A Study Assess Effects Multiple-Dose Probenecid Multiple-Dose Pharmacokinetics Canagliflozin Healthy Volunteers</brief_title>
	<detailed_description>This single-center , open-label ( identity study treatment know volunteer participate study well study staff ) study assess effect multiple dos probenecid multiple-dose pharmacokinetics canagliflozin metabolites healthy volunteer . The study last approximately 49 day ( include Screening Phase 19 day , Open-Label Treatment Phase 20 day , Post-Treatment Phase 7 10 day ) . Healthy volunteer take orally ( mouth ) one 300 mg canagliflozin tablet daily and/or one 500-mg probenecid tablet twice daily sequential order follow : Days 1 14 ( administration canagliflozin alone ) Days 15 17 ( administration canagliflozin + twice-daily administration probenecid ) . On day canagliflozin probenecid take , dose must take approximately time .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<criteria>Body mass index ( BMI ) 18 28 kg/mÂ² inclusive body weight less 50 kg . History current medical illness , abnormal value hematology clinical chemistry laboratory test , abnormal physical examination , vital sign 12lead electrocardiogram ( ECG ) deem clinically significant Investigator</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Probenecid</keyword>
</DOC>